Subscribe

What are you looking for?

Main Menu

明報新聞網

三生製藥與輝瑞簽協議 將收逾60億美元 輝瑞認購1億美元新股

Future Wealths
Future Wealths
20 5 月, 2025
One Min Read
23 Views
0 Comments
三生製藥(1530)公布，與輝瑞就PD-1/VEGF雙特異性抗體(SSGJ-707)訂立許可協議，公司將收到12.5億美元的首付款，並可獲得總額最多為48億美元的潛在付款，及輝瑞可能認購價值1億美元的公司新股份。以目前股價19.24元計，公司市值為460億。

原文: https://finance.mingpao.com/fin/instantf/20250520/1747706162244/%e4%b8%89%e7%94%9f%e8%a3%bd%e8%97%a5%e8%88%87%e8%bc%9d%e7%91%9e%e7%b0%bd%e5%8d%94%e8%ad%b0-%e5%b0%87%e6%94%b6%e9%80%be60%e5%84%84%e7%be%8e%e5%85%83-%e8%bc%9d%e7%91%9e%e8%aa%8d%e8%b3%bc1%e5%84%84%e7%be%8e%e5%85%83%e6%96%b0%e8%82%a1

Last Update: 20 5 月, 2025

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept